GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Equity-to-Asset

AZN (AstraZeneca) Equity-to-Asset : 0.38 (As of Jun. 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AstraZeneca's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $39,512 Mil. AstraZeneca's Total Assets for the quarter that ended in Jun. 2024 was $104,340 Mil. Therefore, AstraZeneca's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.38.

The historical rank and industry rank for AstraZeneca's Equity-to-Asset or its related term are showing as below:

AZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17   Med: 0.24   Max: 0.39
Current: 0.38

During the past 13 years, the highest Equity to Asset Ratio of AstraZeneca was 0.39. The lowest was 0.17. And the median was 0.24.

AZN's Equity-to-Asset is ranked worse than
75.38% of 1040 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs AZN: 0.38

AstraZeneca Equity-to-Asset Historical Data

The historical data trend for AstraZeneca's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Equity-to-Asset Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.23 0.37 0.38 0.39

AstraZeneca Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.39 0.39 0.37 0.38

Competitive Comparison of AstraZeneca's Equity-to-Asset

For the Drug Manufacturers - General subindustry, AstraZeneca's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Equity-to-Asset falls into.



AstraZeneca Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

AstraZeneca's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=39143/101119
=0.39

AstraZeneca's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=39512/104340
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca  (NAS:AZN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


AstraZeneca Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca Headlines

From GuruFocus

FLUMIST approved for self-administration in the US

By Business Wire 09-20-2024